69 related articles for article (PubMed ID: 9428983)
1. Biapenem pharmacokinetics in healthy volunteers and in patients with impaired renal function.
Koeppe P; Höffler D; Fitzen B
Arzneimittelforschung; 1997 Nov; 47(11):1250-6. PubMed ID: 9428983
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of a parenteral carbapenem, biapenem, in patients with end-stage renal disease and influence of haemodialysis.
Nagashima S; Kozawa O; Otsuka T; Kohno K; Minamoto M; Yokokawa M; Kanamaru M; Uematsu T
J Antimicrob Chemother; 2000 Nov; 46(5):839-42. PubMed ID: 11062211
[TBL] [Abstract][Full Text] [Related]
3. An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis.
Sunzel M; Learoyd M; Li J; Li Y; Ngo N; Edeki T
Int J Antimicrob Agents; 2015 Dec; 46(6):682-8. PubMed ID: 26545441
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects.
Kozawa O; Uematsu T; Matsuno H; Niwa M; Takiguchi Y; Matsumoto S; Minamoto M; Niida Y; Yokokawa M; Nagashima S; Kanamaru M
Antimicrob Agents Chemother; 1998 Jun; 42(6):1433-6. PubMed ID: 9624490
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment.
Christensson BA; Nilsson-Ehle I; Hutchison M; Haworth SJ; Oqvist B; Norrby SR
Antimicrob Agents Chemother; 1992 Jul; 36(7):1532-7. PubMed ID: 1510451
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of ceftazidime in normal and impaired renal function.
Höffler D; Koeppe P; Williams KJ
Arzneimittelforschung; 1984; 34(1):72-6. PubMed ID: 6367755
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment.
Leroy A; Fillastre JP; Borsa-Lebas F; Etienne I; Humbert G
Antimicrob Agents Chemother; 1992 Dec; 36(12):2794-8. PubMed ID: 1482147
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 study of L-627, biapenem, a new parenteral carbapenem antibiotic.
Nakashima M; Uematsu T; Ueno K; Nagashima S; Inaba H; Nakano M; Kosuge K; Kitamura M; Sasaki T
Int J Clin Pharmacol Ther Toxicol; 1993 Feb; 31(2):70-6. PubMed ID: 8458679
[TBL] [Abstract][Full Text] [Related]
9. [The pharmacokinetics of ciprofloxacin in patients with renal function of various degrees].
Yu H; Wang HY; Sun ZM
Zhonghua Nei Ke Za Zhi; 1994 Jul; 33(7):449-51. PubMed ID: 7867438
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of meropenem in subjects with renal insufficiency.
Leroy A; Fillastre JP; Etienne I; Borsa-Lebás F; Humbert G
Eur J Clin Pharmacol; 1992; 42(5):535-8. PubMed ID: 1607000
[TBL] [Abstract][Full Text] [Related]
11. Tolerability and pharmacokinetics of biapenem following single and multiple intravenous administrations in healthy Chinese subjects: an open-label, randomized, single-center study.
Liu Y; Li Z; Yang C; Zheng H; Lv Y; Chen H; Zhang Y; Shi S
Drug Res (Stuttg); 2013 Aug; 63(8):396-403. PubMed ID: 23585303
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
Periclou A; Ventura D; Rao N; Abramowitz W
Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
[TBL] [Abstract][Full Text] [Related]
14. The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin.
Nix DE; Schultz RW; Frost RW; Sedman AJ; Thomas DJ; Kinkel AW; Schentag JJ
J Antimicrob Chemother; 1988 Feb; 21 Suppl B():87-95. PubMed ID: 3162906
[TBL] [Abstract][Full Text] [Related]
15. Meropenem clinical pharmacokinetics.
Mouton JW; van den Anker JN
Clin Pharmacokinet; 1995 Apr; 28(4):275-86. PubMed ID: 7648757
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of sulpiride after intravenous administration in patients with impaired renal function.
Bressolle F; Brès J; Mourad G
Clin Pharmacokinet; 1989 Nov; 17(5):367-73. PubMed ID: 2582694
[TBL] [Abstract][Full Text] [Related]
17. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.
Sobue S; Tan K; Layton G; Leclerc V; Weil A
Br J Clin Pharmacol; 2004 Jun; 57(6):773-84. PubMed ID: 15151523
[TBL] [Abstract][Full Text] [Related]
18. Garenoxacin pharmacokinetics in subjects with renal impairment.
Krishna G; Gajjar D; Swan S; Marbury T; Grasela DM; Wang Z
Curr Med Res Opin; 2007 Mar; 23(3):649-57. PubMed ID: 17355746
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the efficacy and safety of biapenem against pneumonia in the elderly and a study on its pharmacokinetics.
Karino F; Deguchi N; Kanda H; Ohe M; Kondo K; Tada M; Kuraki T; Nishimura N; Moriyama H; Ikawa K; Morikawa N; Isobe T
J Infect Chemother; 2013 Feb; 19(1):98-102. PubMed ID: 22926665
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of cefroxadine in healthy volunteers and patients with impaired renal function.
Ohkawa M; Takamae K; Shimamura M; Kuroda K; Awazu S
Chemotherapy; 1981; 27(3):149-54. PubMed ID: 7226971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
